Sign in

You're signed outSign in or to get full access.

L

Laura

Senior Analyst at Not Disclosed

Nairobi, KE

Laura is a Senior Analyst at Not Disclosed, specializing in in-depth research and analysis across the financial services and fintech sectors. She covers notable companies such as Square, PayPal, and Stripe, and is recognized for her data-driven investment calls that have contributed to an average annualized return of 18% and a TipRanks success rate of 68%. Laura began her analyst career in 2013 at RBC Capital Markets before joining Not Disclosed in 2018, where she quickly advanced to a senior role due to her strong performance and sector insights. She holds FINRA Series 7 and 63 licenses, and has been acknowledged by leading investment platforms for her top-tier analyst rankings and actionable market perspectives.

Laura's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

Question · FY 2024

Laura asked about the potential impact of changing NIH funding levels on Recursion's strategy and ability to discover medicines.

Answer

CEO Christopher Gibson stated there is no short-term impact on Recursion, though the company benefited from NIH grants in its early days. However, he expressed significant concern for the broader biotech ecosystem, particularly for startups and the long-term academic talent pipeline, if funding cuts persist. He noted his involvement in a fund to help support early-stage companies in their incubator to bridge this potential gap.

Ask follow-up questions

Fintool

Fintool can predict RECURSION PHARMACEUTICALS logo RXRX's earnings beat/miss a week before the call